Sara Bastian
About
Sara Bastian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Biomaterials.
According to data from OpenAlex, Sara Bastian has authored 18 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Biomaterials. Recurrent topics in Sara Bastian's work include Colorectal Cancer Treatments and Studies (7 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sara Bastian is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sara Bastian collaborates with scholars based in Switzerland, Germany and United States. Sara Bastian's co-authors include Roger von Moos, Susan M. Domchek, Benoît You, Marianne Geiser, Helen K. Angell, Markus Joerger, Christoph Driessen, Ulrich Güller, Susana Banerjee and Richard T. Penson and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.
In The Last Decade
Sara Bastian
16 papers receiving 161 citations
Peers
Sara Bastian
Melanie Ongchin United States
Carlos A. Encarnacion United States
Francesco Grillone Italy
Ming-Mo Hou Taiwan
Yumi Terakado Japan
T. Cameron United States
Matteo Duca Italy
Blanca Navarro Rodrigo Switzerland
Stefania Pipitone Italy
Citations per year, relative to Sara Bastian Sara Bastian (= 1×)
peers
Melanie Ongchin
Countries citing papers authored by Sara Bastian
Since
Specialization
Citations
This map shows the geographic impact of Sara Bastian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Bastian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Bastian more than expected).
Fields of papers citing papers by Sara Bastian
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sara Bastian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Bastian. The network helps show where Sara Bastian may publish in the future.
Co-authorship network of co-authors of Sara Bastian
This figure shows the co-authorship network connecting the top 25 collaborators of Sara Bastian. A scholar is included among the top collaborators of Sara Bastian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Bastian. Sara Bastian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Klose, Martina, Simon Haefliger, Manuela Rabaglio, et al.. (2025). 35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16). ESMO Open. 10. 104193–104193.
2.
Colombo, Ilaria, Simon Haefliger, Manuela Rabaglio, et al.. (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European Journal of Cancer. 201. 113588–113588.
3.
Mark, Michael, Patrizia Froesch, Sacha I. Rothschild, et al.. (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European Journal of Cancer. 200. 113600–113600.
4.
Hess, Dagmar, Robin Michelet, Ilaria Colombo, et al.. (2024). Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemotherapy and Pharmacology. 94(3). 349–360.
5.
Sadlon, Angélique, Ursula Amstutz, Martin D. Berger, et al.. (2024). Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD). International Journal of Molecular Sciences. 25(14). 7599–7599.
6.
Mark, Michael, Patrizia Froesch, Sacha I. Rothschild, et al.. (2023). First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.. Journal of Clinical Oncology. 41(16_suppl). 9088–9088.
7.
Bovet, Cédric, Regula Theurillat, Laurent A. Décosterd, et al.. (2022). Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). British Journal of Clinical Pharmacology. 88(12). 5336–5347.
8.
Bastian, Sara, Markus Joerger, Matthias Gückenberger, et al.. (2022). 431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16. Annals of Oncology. 33. S731–S732.
9.
Gerger, Armin, Wolfgang Eisterer, Sara Bastian, et al.. (2022). Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC. Anticancer Research. 42(10). 4773–4785.
10.
Hess, Dagmar, Ilaria Colombo, Simon Haefliger, et al.. (2022). TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).. Journal of Clinical Oncology. 40(16_suppl). 3027–3027.
11.
Hess, Dagmar, Ilaria Colombo, Simon Haefliger, et al.. (2020). 575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16). Annals of Oncology. 31. S490–S490.
12.
Drew, Yvette, Richard T. Penson, David M. O’Malley, et al.. (2020). 814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Annals of Oncology. 31. S615–S616.
13.
Joerger, Markus, Ulrich Güller, Sara Bastian, Christoph Driessen, & Roger von Moos. (2019). Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 10(2). 373–378.
14.
Domchek, Susan M., S.-A. Im, Y.H. Park, et al.. (2019). Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Annals of Oncology. 30. v477–v477.
15.
Kienle, Dirk, Daniel Dietrich, Karin Ribi, et al.. (2018). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology. 10(2). 304–310.
16.
Kienle, Dirk, Sun Young Rha, Dieter Koeberle, et al.. (2015). 1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. European Journal of Cancer. 51. S194–S195.
17.
Bastian, Sara, Thomas Clerici, Jörg Neuweiler, Thomas Cerny, & Martin Früh. (2011). Surgical Resection of Isolated Adrenal Metastases in Patients with Non-Small Cell Lung Cancer: A Single-Institution Experience and Review of the Literature. Onkologie. 34(12). 665–670.
18.
Geiser, Marianne & Sara Bastian. (2003). Surface-lining layer of airways in cystic fibrosis mice. American Journal of Physiology-Lung Cellular and Molecular Physiology. 285(6). L1277–L1285.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Melanie Ongchin Breakdown of academic impact, for papers by Carlos A. Encarnacion Breakdown of academic impact, for papers by Francesco Grillone Breakdown of academic impact, for papers by Ming-Mo Hou Breakdown of academic impact, for papers by Yumi Terakado Breakdown of academic impact, for papers by T. Cameron Breakdown of academic impact, for papers by Matteo Duca Breakdown of academic impact, for papers by Blanca Navarro Rodrigo Breakdown of academic impact, for papers by Stefania Pipitone